Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison
Authors' conclusion
Currently there are no direct comparisons of tirzepatide and semaglutide for weight management. Using the matching-adjusted indirect treatment comparison method to compare the efficacy of tirzepatide and semaglutide for chronic weight management, this analysis showed greater weight loss with tirzepatide 10 and 15 mg versus semaglutide 2.4 mg.
Study context
- Population
- Participants with obesity in the SURMOUNT-1 and STEP 1 trials
- Comparison
- Tirzepatide 10 and 15 mg vs semaglutide 2.4 mg
- Outcome
- Mean percentage change in body weight from baseline and OR of achieving ≥5% weight loss
- Follow-up
- Tirzepatide week 72; semaglutide week 68
Methodological detailsmatching-adjusted indirect comparison, efficacy estimand, sensitivity analyses incl. Bucher method
- Matching-adjusted indirect comparison
- Efficacy estimand
- Sensitivity analyses incl. Bucher method
Main finding
As reported in the abstract
Percentage change in body weight
Each group vs semaglutide 2.4 mgMean difference, % (95% CI)P value
Tirzepatide 10 mg
−4.67(−5.91% to −3.43%)
P < 0.001Tirzepatide 15 mg
−5.92(−7.16% to −4.68%)
P < 0.001Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Achieving ≥5% weight lossTirzepatide 10 mgvs Semaglutide 2.4 mg | 2.61 (1.48–4.57) | P < 0.001 | |
| Achieving ≥5% weight lossTirzepatide 15 mgvs Semaglutide 2.4 mg | 2.75 (1.57–4.81) | P < 0.001 | |
| 0.20.5125Odds ratio (log scale) |
Sensitivity analyses
- All consistent, except OR of ≥5% weight loss with tirzepatide 10 mg by Bucher method, treatment regimen estimand
- P = 0.074
Original publication
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison. Diabetes Obes Metab. Published 21 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →